NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
Clinical Trials
19 trialsNCT06235697 2026-04-14
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT02489318 2026-04-13
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT03767244 2026-04-13
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04108208 2026-04-13
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT07340541 2026-04-13
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT04787744 2026-04-08
VA STARPORT
VA Office of Research and Development
Phase 2/3 Recruiting
NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03543189 2026-04-01
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT06244004 2026-03-30
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT07490210 2026-03-24
OMPC-RPM
Fudan University
Phase 2 Not yet recruiting
NCT07426055 2026-03-23
PRO-BOOST-LC
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Phase 2/3 Recruiting
NCT07426094 2026-03-23
PRO-BOOST-N
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Phase 2/3 Recruiting
NCT04191096 2026-03-20
KEYNOTE-991
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05477823 2026-03-20
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
University of Wisconsin, Madison
Phase EARLY_PHASE1 Active not recruiting
NCT06661122 2026-03-19
HAYATE
Bayer
Recruiting
NCT07483658 2026-03-19
HYP-OP-RT
CHU de Quebec-Universite Laval
Phase NA Not yet recruiting
NCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed